Prevalence of muscle dysmorphia in adolescents: findings from the


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 17 3 2021
medline: 5 1 2023
entrez: 16 3 2021
Statut: ppublish

Résumé

We sought to provide the first point prevalence estimates of muscle dysmorphia (MD), a form of body dysmorphic disorder characterized by a preoccupation with perceived insufficient muscularity, in adolescents. Data were taken from a survey of 3618 Australian adolescents (11.172-19.76 years; 49.3% girls). Measures captured demographic characteristics, symptoms of MD and eating disorders, psychological distress and functional impairment. Diagnostic criteria for MD developed by Pope et al. (1997, The point prevalence of MD was 2.2% [95% confidence interval (CI) 1.6-3.0%] among boys and 1.4% (95% CI 0.9-2.0%) among girls. Prevalence was not associated with gender ( While future epidemiological research using diagnostic interviews is needed to verify these estimates, the findings suggest that MD is relatively common from early to late adolescence. Gender differences in MD prevalence may be minimal; however, the symptom profile appears to diverge between boys and girls. These findings provide a platform for future, analytical research designed to inform clinical and public health interventions.

Sections du résumé

BACKGROUND
We sought to provide the first point prevalence estimates of muscle dysmorphia (MD), a form of body dysmorphic disorder characterized by a preoccupation with perceived insufficient muscularity, in adolescents.
METHODS
Data were taken from a survey of 3618 Australian adolescents (11.172-19.76 years; 49.3% girls). Measures captured demographic characteristics, symptoms of MD and eating disorders, psychological distress and functional impairment. Diagnostic criteria for MD developed by Pope et al. (1997,
RESULTS
The point prevalence of MD was 2.2% [95% confidence interval (CI) 1.6-3.0%] among boys and 1.4% (95% CI 0.9-2.0%) among girls. Prevalence was not associated with gender (
CONCLUSIONS
While future epidemiological research using diagnostic interviews is needed to verify these estimates, the findings suggest that MD is relatively common from early to late adolescence. Gender differences in MD prevalence may be minimal; however, the symptom profile appears to diverge between boys and girls. These findings provide a platform for future, analytical research designed to inform clinical and public health interventions.

Identifiants

pubmed: 33722325
doi: 10.1017/S0033291720005206
pii: S0033291720005206
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3142-3149

Auteurs

Deborah Mitchison (D)

Translational Health Research Institute, School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Department of Psychology, Centre for Emotional Health, North Ryde, NSW, Australia.

Jonathan Mond (J)

Centre for Rural Health, University of Tasmania, Launceston, TAS, Australia.

Scott Griffiths (S)

Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, VIC, Australia.

Phillipa Hay (P)

Translational Health Research Institute, School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Camden and Campbelltown Hospitals, SWSLHD, Camden and Campbelltown, NSW, Australia.

Jason M Nagata (JM)

Department of Pediatrics, University of California, San Francisco, CA, USA.

Kay Bussey (K)

Department of Psychology, Centre for Emotional Health, North Ryde, NSW, Australia.

Nora Trompeter (N)

Department of Psychology, Centre for Emotional Health, North Ryde, NSW, Australia.

Alexandra Lonergan (A)

Department of Psychology, Centre for Emotional Health, North Ryde, NSW, Australia.

Stuart B Murray (SB)

Department of Psychiatry & Behavioral Sciences, University of Southern California, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH